Difference in mean utility for selected complications (grouped by 4 classes of algorithms)

<p><b>Copyright information:</b></p><p>Taken from "Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial"</p><p>http://www.hqlo.com/content/5/1/21</p><p>Health and Quality of Life Outcomes 2007;5():21-21.</p><p>Published online 27 Apr 2007</p><p>PMCID:PMC1950473.</p><p></p

Mean deficit (and 95% CIs) in utility value at study baseline for patients with selected medical condition

<p><b>Copyright information:</b></p><p>Taken from "Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial"</p><p>http://www.hqlo.com/content/5/1/21</p><p>Health and Quality of Life Outcomes 2007;5():21-21.</p><p>Published online 27 Apr 2007</p><p>PMCID:PMC1950473.</p><p></p

Estimated excess costs per annum for 15 disease comorbidity pairs for 45–49- and 75–79-year-olds, using the six-disease models in Table 3.

CVD, cardiovascular disease; DM, diabetes mellitus; LLK, lung/liver/kidney; MS, musculoskeletal; Neuro, neurological.</p

Descriptive data of observation counts and expenditure (US$ 2016) by sex, age, and financial year.

Descriptive data of observation counts and expenditure (US$ 2016) by sex, age, and financial year.</p

Observation counts and expenditure (in US$ millions, 2016) by diseases, by phase, and by disease comorbidity combinations.

Observation counts and expenditure (in US$ millions, 2016) by diseases, by phase, and by disease comorbidity combinations.</p

Independent disease expenditure per annum per person by disease phase (i.e., mutually exclusive between diseases, not allowing for disease comorbidity interactions; US$ 2016).

CKD, chronic kidney disease; CLD, chronic liver disease; CVD, cardiovascular disease; IHD, ischaemic heart disease.</p

Population-level total costs and cause-deleted cost savings in absolute dollars (US$ millions) and as a percentage of cost savings from deleting all diseases.

Population-level total costs and cause-deleted cost savings in absolute dollars (US$ millions) and as a percentage of cost savings from deleting all diseases.</p

Annual excess health spending (US$ 2016) for NCDs (6 and 13 disease groupings) predicted by OLS regression for 60–64-year-olds†.

Annual excess health spending (US$ 2016) for NCDs (6 and 13 disease groupings) predicted by OLS regression for 60–64-year-olds†.</p

Appendices_online_supp – Supplemental material for Exploring the Impact of Quality of Life on Survival: A Case Study in Total Knee Replacement Surgery

Supplemental material, Appendices_online_supp for Exploring the Impact of Quality of Life on Survival: A Case Study in Total Knee Replacement Surgery by Michelle Tew, Kim Dalziel, Michelle Dowsey, Peter F. Choong and Philip Clarke in Medical Decision Making</p

Additional file 1: of The impact of Medicare part D on income-related inequality in pharmaceutical expenditure

Table S1. Selected years’ CI in drug expenditure. Figure S1. Income-related inequality in drug expenditure (CI) from all sources. Figure S2. Income-related inequality in drug expenditure (GCI) from all sources. Figure S3. Inequality in directly standardised drug expenditure (CI). Figure S4. Inequality in indirectly standardised drug expenditure (CI). Figure S5. Weighted average public drug expenditure by income decile pre- and post- Medicare Part D (for the over 65s). Table S2. Coefficients of directly standardised equations of public drug expenditure. Figure S6. Decomposition of directly standardised CI (over 65s). Table S3. Difference-in-differences estimation in CI and GCI of drug expenditure. Table S4. Difference-in-differences estimation in CI and GCI of drug expenditure. Table S5. Difference-in-differences estimation in mean, CI and GCI of drug expenditure. Table S6. Difference-in-differences estimation in mean, CI and GCI of drug expenditure. (DOCX 1402 kb